Investor Relations
Corporate Profile
Apollomics Inc. is a clinical-stage biopharmaceutical company developing oncology therapies that target key molecular pathways and harness the immune system. Its pipeline includes nine drug candidates, six in clinical development, led by vebreltinib, a selective c-Met inhibitor for advanced tumors, and uproleselan (APL-106), an E-selectin antagonist being studied in acute myeloid leukemia.
Latest Earnings
Q4
2026
Lorem Ipsum
Lorem Ipsum
Latest News and Events
09:30
03 Jul
Item Title
Use this space to promote the business, its products or its services.
12:30
03 Jul
Item Title
Use this space to promote the business, its products or its services.
16:00
03 Jul
Item Title
Use this space to promote the business, its products or its services.
09:30
03 Jul
Item Title
Use this space to promote the business, its products or its services.
12:30
03 Jul
Item Title
Use this space to promote the business, its products or its services.
16:00
03 Jul
Item Title
Use this space to promote the business, its products or its services.